Ranking the best states for healthcare highlights where more work is needed.
Good healthcare is hard to exactly define. What measurements are or aren’t important? What defines a healthy population?To help answer those questions, as well as to gain a better picture of where healthcare measurements are lacking, MoneyRates.com created a proprietary study of the best and worst states for healthcare. It ranked all 50 states plus the District of Columbia based on seven different factors: health insurance coverage, age-adjusted mortality, vaccination rates, infant mortality, nursing-home availability, hospital availability and practicing physicians per capita. Ranks across the seven categories were averaged, and those averages were used to rank the states overall.As for overall landscape of what healthcare looks like in the U.S., it can vary widely by location, according to Richard Barrington, senior financial analyst, MoneyRates.com“It depends on where you look, because the differences in conditions are jarring. For example, more than 40% of the kids in Oregon are unvaccinated, which is worse than twice the national average,” Barrington says. “More than 17% of people in Texas lack health insurance, which is more than six times the percentage uninsured in Massachusetts. Our study found contrasts like that across a range of different criteria.”Related article: Top 10 States with the Highest Drug Use ProblemsUnderstanding those differences highlights challenges-and opportunities-for healthcare executives.“For health executives and policymakers, these rankings can be viewed as a report card of areas that perform well and areas that need improvement,” says Barrington. “From a business standpoint, health executives can also look at areas needing improvement as an opportunity. For example, even Massachusetts, which ranked as the best state overall, was among the worst for available hospital capacity. That could be an opportunity for someone to provide that capacity. This study could interest health executives from the standpoint of showing where supply is not meeting demand in their home states and where opportunities might exist to provide what they do well in other states.”Below is a summary of where the top 10 best and worst states ranked and why. For more specifics on the strengths and weaknesses of particular states, please see the comparison tool within this article. Â
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More